title: Letter to the editor. [letter].
authors.affiliation: Abbott Laboratories, Abbott Park, IL.
authors.forename: A
authors.initials: A
authors.lastname: Hsu
authors.forename: D
authors.initials: D
authors.lastname: Kempf
authors.forename: J
authors.initials: J
authors.lastname: Leonard
authors.forename: R
authors.initials: R
authors.lastname: Mills
mesh_terms: D065607:Cytochrome P-450 Enzyme Inhibitors; D017277:Drug Approval; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015497:HIV-1 / Q000187:drug effects; D007527:Isoenzymes / Q000037:antagonists & inhibitors; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D065607:Cytochrome P-450 Enzyme Inhibitors; D017320:HIV Protease Inhibitors; D007527:Isoenzymes